shutterstock_1492661771_ricochet64
ricochet64 / Shutterstock.com
4 June 2020Big PharmaSarah Morgan

English court gives Mylan green-light to sell generic insomnia drug

In a victory for  Mylan, the English High Court has rejected Israel-based pharmaceutical company  Neurim’s attempt to delay a generic version of its insomnia medication.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
3 June 2020   Israeli generic drugmaker Teva Pharmaceuticals must face infringement claims related to an asthma inhaler, an English judge has ruled.
Big Pharma
17 March 2020   The US Court of Appeals for the Federal Circuit has rescued one Boehringer Ingelheim patent, covering a type 2 diabetes treatment, from invalidation but affirmed a New Jersey district court’s cancellation of two others.
Big Pharma
26 June 2020   The English Court of Appeal has rejected Neurim’s attempt to block sales of a generic version of its insomnia drug made by Mylan ahead of a patent infringement trial.

More on this story

Europe
3 June 2020   Israeli generic drugmaker Teva Pharmaceuticals must face infringement claims related to an asthma inhaler, an English judge has ruled.
Big Pharma
17 March 2020   The US Court of Appeals for the Federal Circuit has rescued one Boehringer Ingelheim patent, covering a type 2 diabetes treatment, from invalidation but affirmed a New Jersey district court’s cancellation of two others.
Big Pharma
26 June 2020   The English Court of Appeal has rejected Neurim’s attempt to block sales of a generic version of its insomnia drug made by Mylan ahead of a patent infringement trial.

More on this story

Europe
3 June 2020   Israeli generic drugmaker Teva Pharmaceuticals must face infringement claims related to an asthma inhaler, an English judge has ruled.
Big Pharma
17 March 2020   The US Court of Appeals for the Federal Circuit has rescued one Boehringer Ingelheim patent, covering a type 2 diabetes treatment, from invalidation but affirmed a New Jersey district court’s cancellation of two others.
Big Pharma
26 June 2020   The English Court of Appeal has rejected Neurim’s attempt to block sales of a generic version of its insomnia drug made by Mylan ahead of a patent infringement trial.